Replimune Group (NASDAQ: REPL)
Replimune Group Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Replimune Group Company Info
Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
News & Analysis
2 Biotech Stocks That Could Have Tripled Your Money This Year
One has a better chance to keep climbing than the other does.
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.